-
1
-
-
0003426141
-
-
NCI: Bethesda, MD
-
Howlader N NA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2011, NCI: Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975-2010/.
-
SEER Cancer Statistics Review, 1975-2011
-
-
Howlader, N.N.A.1
Krapcho, M.2
Garshell, J.3
Miller, D.4
Altekruse, S.F.5
Kosary, C.L.6
-
2
-
-
84875690627
-
Latest research and treatment of advanced-stage epithelial ovarian cancer
-
Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10: 211-24.
-
(2013)
Nat Rev Clin Oncol
, vol.10
, pp. 211-224
-
-
Coleman, R.L.1
Monk, B.J.2
Sood, A.K.3
Herzog, T.J.4
-
3
-
-
84886802501
-
The role of the fallopian tube in the origin of ovarian cancer
-
Erickson BK, Conner MG, LandenCNJr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 2013;209:409-14.
-
(2013)
Am J Obstet Gynecol
, vol.209
, pp. 409-414
-
-
Erickson, B.K.1
Conner, M.G.2
Landen, C.N.3
-
4
-
-
47549085187
-
Phenotypic plasticity of neoplastic ovarian epithelium: Unique cadherin profiles in tumor progression
-
Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 2008;25:643-55.
-
(2008)
Clin Exp Metastasis
, vol.25
, pp. 643-655
-
-
Hudson, L.G.1
Zeineldin, R.2
Stack, M.S.3
-
5
-
-
84925966184
-
Exploiting the critical perioperative period to improve long-term cancer outcomes
-
Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 2015;12:213-26.
-
(2015)
Nat Rev Clin Oncol
, vol.12
, pp. 213-226
-
-
Horowitz, M.1
Neeman, E.2
Sharon, E.3
Ben-Eliyahu, S.4
-
6
-
-
84868093750
-
NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: Particular relevance to triple negative subgroup
-
Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat 2012;134:881-8.
-
(2012)
Breast Cancer Res Treat
, vol.134
, pp. 881-888
-
-
Retsky, M.1
Rogers, R.2
Demicheli, R.3
Hrushesky, W.J.4
Gukas, I.5
Vaidya, J.S.6
-
7
-
-
84908424942
-
Rho GTPases: Masters of cell migration
-
Sadok A, Marshall CJ. Rho GTPases: masters of cell migration. Small GTPases 2014;5:e29710.
-
(2014)
Small GTPases
, vol.5
, pp. e29710
-
-
Sadok, A.1
Marshall, C.J.2
-
8
-
-
84862550404
-
Rho GTPase signaling in the development of colorectal cancer
-
Leve F, Morgado-Diaz JA. Rho GTPase signaling in the development of colorectal cancer. J Cell Biochem 2012;113:2549-59.
-
(2012)
J Cell Biochem
, vol.113
, pp. 2549-2559
-
-
Leve, F.1
Morgado-Diaz, J.A.2
-
9
-
-
84878650360
-
Role of activated rac1/cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer
-
Ma J, Xue Y, Liu W, Yue C, Bi F, Xu J, et al. Role of activated rac1/cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer. PLoS ONE 2013;8:e66275.
-
(2013)
PLoS ONE
, vol.8
, pp. e66275
-
-
Ma, J.1
Xue, Y.2
Liu, W.3
Yue, C.4
Bi, F.5
Xu, J.6
-
11
-
-
84938058544
-
Rac1 expression in epithelial ovarian cancer: Effect on cell EMT and clinical outcome
-
Leng R, Liao G, Wang H, Kuang J, Tang L. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome. Med Oncol 2015;32:329.
-
(2015)
Med Oncol
, vol.32
, pp. 329
-
-
Leng, R.1
Liao, G.2
Wang, H.3
Kuang, J.4
Tang, L.5
-
12
-
-
84946818704
-
A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients
-
Jun 12. [Epub ahead of print]
-
Guo Y, Kenney SR, Cook L, Adams S, Rutledge T, Romero E, et al. A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients. Clin Cancer Res. 2015 Jun 12. [Epub ahead of print].
-
(2015)
Clin Cancer Res.
-
-
Guo, Y.1
Kenney, S.R.2
Cook, L.3
Adams, S.4
Rutledge, T.5
Romero, E.6
-
13
-
-
84863968373
-
Molecular pathways: Targeting p21-activated kinase 1 signaling in cancer-opportunities, challenges, and limitations
-
Eswaran J, Li DQ, Shah A, Kumar R. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer-opportunities, challenges, and limitations. Clin Cancer Res 2012;18:3743-9.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3743-3749
-
-
Eswaran, J.1
Li, D.Q.2
Shah, A.3
Kumar, R.4
-
14
-
-
84907445756
-
Molecular pathways: Targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers
-
Baker NM, Yee Chow H, Chernoff J, Der CJ. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin Cancer Res 2014;20:4740-6.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 4740-4746
-
-
Baker, N.M.1
Yee Chow, H.2
Chernoff, J.3
Der, C.J.4
-
15
-
-
84930651943
-
Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer
-
Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, et al. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clin Cancer Res 2015;21:2127-37.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2127-2137
-
-
Gonzalez-Villasana, V.1
Fuentes-Mattei, E.2
Ivan, C.3
Dalton, H.J.4
Rodriguez-Aguayo, C.5
Fernandez-De Thomas, R.J.6
-
16
-
-
84894498866
-
Rac1-mediated effects of HMG-CoA reductase inhibitors (Statins) in cardiovascular disease
-
Adam O, Laufs U. Rac1-mediated effects of HMG-CoA reductase inhibitors (Statins) in cardiovascular disease. Antioxid Redox Signal 2014;20: 1238-50.
-
(2014)
Antioxid Redox Signal
, vol.20
, pp. 1238-1250
-
-
Adam, O.1
Laufs, U.2
-
17
-
-
84891107346
-
Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer
-
Sendur MA, Aksoy S, Yazici O, Ozdemir NY, Zengin N, Altundag K. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. Med Oncol 2014;31:835.
-
(2014)
Med Oncol
, vol.31
, pp. 835
-
-
Sendur, M.A.1
Aksoy, S.2
Yazici, O.3
Ozdemir, N.Y.4
Zengin, N.5
Altundag, K.6
-
18
-
-
84907478534
-
Statin use after colorectal cancer diagnosis and survival: A population-based cohort study
-
Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 2014;32:3177-83.
-
(2014)
J Clin Oncol
, vol.32
, pp. 3177-3183
-
-
Cardwell, C.R.1
Hicks, B.M.2
Hughes, C.3
Murray, L.J.4
-
19
-
-
84927087932
-
Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study
-
Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer 2015; 121:1287-94.
-
(2015)
Cancer
, vol.121
, pp. 1287-1294
-
-
Walker, E.J.1
Ko, A.H.2
Holly, E.A.3
Bracci, P.M.4
-
20
-
-
84905906596
-
Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: A retrospective cohort analysis
-
Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, et al. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS ONE 2014;9:e104521.
-
(2014)
PLoS ONE
, vol.9
, pp. e104521
-
-
Habis, M.1
Wroblewski, K.2
Bradaric, M.3
Ismail, N.4
Yamada, S.D.5
Litchfield, L.6
-
21
-
-
2442664118
-
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
-
Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004;101:7618-23.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 7618-7623
-
-
Gao, Y.1
Dickerson, J.B.2
Guo, F.3
Zheng, J.4
Zheng, Y.5
-
22
-
-
33645240619
-
Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro
-
Pelish HE, Peterson JR, Salvarezza SB, Rodriguez-Boulan E, Chen JL, Stamnes M, et al. Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nat Chem Biol 2006;2:39-46.
-
(2006)
Nat Chem Biol
, vol.2
, pp. 39-46
-
-
Pelish, H.E.1
Peterson, J.R.2
Salvarezza, S.B.3
Rodriguez-Boulan, E.4
Chen, J.L.5
Stamnes, M.6
-
23
-
-
84875457631
-
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe
-
Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth J, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem 2013;288:8531-43.
-
(2013)
J Biol Chem
, vol.288
, pp. 8531-8543
-
-
Hong, L.1
Kenney, S.R.2
Phillips, G.K.3
Simpson, D.4
Schroeder, C.E.5
Noth, J.6
-
24
-
-
0034017744
-
Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases
-
Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000;57:976-83.
-
(2000)
Mol Pharmacol
, vol.57
, pp. 976-983
-
-
Ishizaki, T.1
Uehata, M.2
Tamechika, I.3
Keel, J.4
Nonomura, K.5
Maekawa, M.6
-
25
-
-
84946818705
-
Selected NSAIDs targetGTPases for ovariancancer therapy
-
[abstract]. Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res: Abstract nr B81
-
Guo Y, Kenney SR, Romero R, Oprea T, Adams S, Muller C, et al. Selected NSAIDs targetGTPases for ovariancancer therapy. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl): Abstract nr B81.
-
(2013)
Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic
, vol.19
, Issue.19
-
-
Guo, Y.1
Kenney, S.R.2
Romero, R.3
Oprea, T.4
Adams, S.5
Muller, C.6
-
26
-
-
84946818706
-
-
Mississauga, Ontario [cited 2015 Feb 19]
-
® [Internet]. Mississauga, Ontario [cited 2015 Feb 19]. Available from: http://www.rochecanada.com/content/dam/internet/corporate/rochecanada/en-CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Toradol/Toradol-PM-CIE.pdf.
-
® [Internet]
-
-
-
28
-
-
0033028718
-
Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat
-
Jett MF, Ramesha CS, Brown CD, Chiu S, Emmett C, Voronin T, et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 1999;288: 1288-97.
-
(1999)
J Pharmacol Exp Ther
, vol.288
, pp. 1288-1297
-
-
Jett, M.F.1
Ramesha, C.S.2
Brown, C.D.3
Chiu, S.4
Emmett, C.5
Voronin, T.6
-
29
-
-
84892798809
-
Neutrophil: Lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery
-
Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B, et al. Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 2013;20 Suppl 3: S650-60.
-
(2013)
Ann Surg Oncol
, vol.20
, pp. S650-S660
-
-
Forget, P.1
Machiels, J.P.2
Coulie, P.G.3
Berliere, M.4
Poncelet, A.J.5
Tombal, B.6
-
30
-
-
84946749324
-
Peri-operative ketorolac is associated with improved epithelial ovarian cancer survival
-
Mahller Y, Walsh C, Cass I, Rimel B, Karlan B, Li A. Peri-operative ketorolac is associated with improved epithelial ovarian cancer survival. Gynecol Oncol 2012;127:S25.
-
(2012)
Gynecol Oncol
, vol.127
, pp. S25
-
-
Mahller, Y.1
Walsh, C.2
Cass, I.3
Rimel, B.4
Karlan, B.5
Li, A.6
-
31
-
-
84868138680
-
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: The DoCaCel study
-
Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, et al. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol 2012; 23:2896-902.
-
(2012)
Ann Oncol
, vol.23
, pp. 2896-2902
-
-
Reyners, A.K.1
De Munck, L.2
Erdkamp, F.L.3
Smit, W.M.4
Hoekman, K.5
Lalisang, R.I.6
-
32
-
-
84883765692
-
Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial
-
Forget P, Berliere M, van Maanen A, Duhoux FP, Machiels JP, Coulie PG, et al. Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Med Hypotheses 2013;81:707-12.
-
(2013)
Med Hypotheses
, vol.81
, pp. 707-712
-
-
Forget, P.1
Berliere, M.2
Van Maanen, A.3
Duhoux, F.P.4
Machiels, J.P.5
Coulie, P.G.6
-
33
-
-
50049120233
-
Flow cytometry for real-time measurement of guanine nucleotide binding and exchange by Ras-like GTPases
-
Schwartz SL, Tessema M, Buranda T, Pylypenko O, Rak A, Simons PC, et al. Flow cytometry for real-time measurement of guanine nucleotide binding and exchange by Ras-like GTPases. Anal Biochem 2008;381:258-66.
-
(2008)
Anal Biochem
, vol.381
, pp. 258-266
-
-
Schwartz, S.L.1
Tessema, M.2
Buranda, T.3
Pylypenko, O.4
Rak, A.5
Simons, P.C.6
-
34
-
-
84885449964
-
Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells
-
Jacob A, Jing J, Lee J, Schedin P, Gilbert SM, Peden AA, et al. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. J Cell Sci 2013;126:4647-58.
-
(2013)
J Cell Sci
, vol.126
, pp. 4647-4658
-
-
Jacob, A.1
Jing, J.2
Lee, J.3
Schedin, P.4
Gilbert, S.M.5
Peden, A.A.6
-
36
-
-
34447345507
-
Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients
-
Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 2006;1:2643-9.
-
(2006)
Nat Protoc
, vol.1
, pp. 2643-2649
-
-
Shepherd, T.G.1
Theriault, B.L.2
Campbell, E.J.3
Nachtigal, M.W.4
-
37
-
-
84862549205
-
A competitive nucleotide binding inhibitor: In vitro characterization of Rab7 GTPase inhibition
-
Agola JO, Hong L, Surviladze Z, Ursu O, Waller A, Strouse JJ, et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem Biol 2012;7:1095-108.
-
(2012)
ACS Chem Biol
, vol.7
, pp. 1095-1108
-
-
Agola, J.O.1
Hong, L.2
Surviladze, Z.3
Ursu, O.4
Waller, A.5
Strouse, J.J.6
-
38
-
-
84884483633
-
Rapid parallel flow cytometry assays of active GTPases using effector beads
-
Buranda T, Basuray S, Swanson S, Agola J, Bondu V, Wandinger-Ness A. Rapid parallel flow cytometry assays of active GTPases using effector beads. Anal Biochem 2013;442:149-57.
-
(2013)
Anal Biochem
, vol.442
, pp. 149-157
-
-
Buranda, T.1
Basuray, S.2
Swanson, S.3
Agola, J.4
Bondu, V.5
Wandinger-Ness, A.6
-
39
-
-
0034971799
-
Cell adhesion assays
-
Humphries MJ. Cell adhesion assays. Mol Biotechnol 2001;18:57-61.
-
(2001)
Mol Biotechnol
, vol.18
, pp. 57-61
-
-
Humphries, M.J.1
-
40
-
-
69449087383
-
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-specific immunotherapy
-
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer 2009;19:860-6.
-
(2009)
Int J Gynecol Cancer
, vol.19
, pp. 860-866
-
-
Bellone, S.1
Siegel, E.R.2
Cocco, E.3
Cargnelutti, M.4
Silasi, D.A.5
Azodi, M.6
-
41
-
-
69249213928
-
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer
-
Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009;115:112-20.
-
(2009)
Gynecol Oncol
, vol.115
, pp. 112-120
-
-
Taylor, D.D.1
Gercel-Taylor, C.2
Parker, L.P.3
-
42
-
-
84879101332
-
PAK family kinases: Physiological roles and regulation
-
Zhao ZS, Manser E. PAK family kinases: physiological roles and regulation. Cell Logist 2012;2:59-68.
-
(2012)
Cell Logist
, vol.2
, pp. 59-68
-
-
Zhao, Z.S.1
Manser, E.2
-
44
-
-
0032478605
-
A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids
-
Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S, et al. A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids. J Biol Chem 1998;273:8137-44.
-
(1998)
J Biol Chem
, vol.273
, pp. 8137-8144
-
-
Bokoch, G.M.1
Reilly, A.M.2
Daniels, R.H.3
King, C.C.4
Olivera, A.5
Spiegel, S.6
-
45
-
-
84879640742
-
Cyclooxygenase-2 deficiency in macrophages leads to defective p110gamma PI3K signaling and impairs cell adhesion and migration
-
Diaz-Munoz MD, Osma-Garcia IC, Iniguez MA, Fresno M. Cyclooxygenase-2 deficiency in macrophages leads to defective p110gamma PI3K signaling and impairs cell adhesion and migration. J Immunol 2013;191: 395-406.
-
(2013)
J Immunol
, vol.191
, pp. 395-406
-
-
Diaz-Munoz, M.D.1
Osma-Garcia, I.C.2
Iniguez, M.A.3
Fresno, M.4
-
46
-
-
80053444351
-
Filopodia and adhesion in cancer cell motility
-
Arjonen A, Kaukonen R, Ivaska J. Filopodia and adhesion in cancer cell motility. Cell Adh Migr 2011;5:421-30.
-
(2011)
Cell Adh Migr
, vol.5
, pp. 421-430
-
-
Arjonen, A.1
Kaukonen, R.2
Ivaska, J.3
-
47
-
-
44349179335
-
Filopodia: Molecular architecture and cellular functions
-
Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol 2008;9:446-54.
-
(2008)
Nat Rev Mol Cell Biol
, vol.9
, pp. 446-454
-
-
Mattila, P.K.1
Lappalainen, P.2
-
48
-
-
84856287423
-
Cell migration and invasion in human disease: The Tks adaptor proteins
-
Courtneidge SA. Cell migration and invasion in human disease: the Tks adaptor proteins. Biochem Soc Trans 2012;40:129-32.
-
(2012)
Biochem Soc Trans
, vol.40
, pp. 129-132
-
-
Courtneidge, S.A.1
-
49
-
-
70249105718
-
Activation of RhoGTPases by DOCK exchange factors is mediated by a nucleotide sensor
-
Yang J, Zhang Z, Roe SM, Marshall CJ, Barford D. Activation of RhoGTPases by DOCK exchange factors is mediated by a nucleotide sensor. Science 2009;325:1398-402.
-
(2009)
Science
, vol.325
, pp. 1398-1402
-
-
Yang, J.1
Zhang, Z.2
Roe, S.M.3
Marshall, C.J.4
Barford, D.5
-
50
-
-
78049405035
-
Molecular basis for cyclooxygenase inhibition by the nonsteroidal anti-inflammatory drug naproxen
-
Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA, et al. Molecular basis for cyclooxygenase inhibition by the nonsteroidal anti-inflammatory drug naproxen. J Biol Chem 2010;285: 34950-9.
-
(2010)
J Biol Chem
, vol.285
, pp. 34950-34959
-
-
Duggan, K.C.1
Walters, M.J.2
Musee, J.3
Harp, J.M.4
Kiefer, J.R.5
Oates, J.A.6
-
51
-
-
77953218308
-
Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis
-
Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg 2010;110:1630-5.
-
(2010)
Anesth Analg
, vol.110
, pp. 1630-1635
-
-
Forget, P.1
Vandenhende, J.2
Berliere, M.3
Machiels, J.P.4
Nussbaum, B.5
Legrand, C.6
-
52
-
-
0034791297
-
NSAIDs inhibit alpha v beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis
-
Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001;7:1041-7.
-
(2001)
Nat Med
, vol.7
, pp. 1041-1047
-
-
Dormond, O.1
Foletti, A.2
Paroz, C.3
Ruegg, C.4
-
53
-
-
84885611918
-
RAC1: An emerging therapeutic option for targeting cancer angiogenesis and metastasis
-
Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther 2013;12:1925-34.
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 1925-1934
-
-
Bid, H.K.1
Roberts, R.D.2
Manchanda, P.K.3
Houghton, P.J.4
|